Rapid preparation of stem cell matrices for use in tissue and organ treatment and repair

• US 20020155096A1
• Filed: 02/22/2002
• Published: 10/24/2002
• Est. Priority Date: 02/23/2001
• Status: Abandoned Application

• Current Assignee: University Of Pittsburgh (University of Pittsburgh of The Commonwealth System of Higher Education)
• Original Assignee: University Of Pittsburgh (University of Pittsburgh of The Commonwealth System of Higher Education)
• Inventors: Sacks, Michael S., Chancellor, Michael B., Huard, Johnny, Chung, Steve, Capelli, Christopher
• Application Number:
  US10/081,835
• Publication Number:
  US 20020155096A1
• Time in Patent Office: Days
• US Class Current: 424/93.7
• CPC Class Codes: A61K 35/12 Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells vaccines or medicinal preparations containing antigens or antibodies A61K39/00
• CPC Class Codes: A61L 2430/22 for reconstruction of hollow organs, e.g. bladder, esophagus, urether, uterus
• CPC Class Codes: A61L 27/225 Fibrin; Fibrinogen
• CPC Class Codes: A61L 27/3629 Intestinal tissue, e.g. small intestinal submucosa
• CPC Class Codes: A61L 27/3679 Hollow organs, e.g. bladder, esophagus, urether, uterus, intestine
• CPC Class Codes: A61L 27/3834 Cells able to produce different cell types, e.g. hematopoietic stem cells, mesenchymal stem cells, marrow stromal cells, embryonic stem cells
• CPC Class Codes: A61P 17/02 for treating wounds, ulcers, burns, scars, keloids, or the like
• CPC Class Codes: A61P 21/00 Drugs for disorders of the muscular or neuromuscular system
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system
• CPC Class Codes: C12N 2533/56 Fibrin; Thrombin
• CPC Class Codes: C12N 2533/74 Alginate
• CPC Class Codes: C12N 2533/90 Substrates of biological origin, e.g. extracellular matrix, decellularised tissue
• CPC Class Codes: C12N 2533/92 Amnion; Decellularised dermis or mucosa
• CPC Class Codes: C12N 5/0068 General culture methods using substrates for specific animal cell type C12N5/06
• CPC Class Codes: C12N 5/0658 Skeletal muscle cells, e.g. myocytes, myotubes, myoblasts
• CPC Class Codes: C12N 5/0668 Mesenchymal stem cells from other natural sources
• CPC Class Codes: C12N 5/0697 Artificial constructs associating cells of different lineages, e.g. tissue equivalents blood vessels C12N5/0691

Abstract

The present invention describes a rapid method for preparing stem cell and physiologically acceptable matrix compositions for use in tissue and organ repair. Compared with previous tissue engineering materials, the stem cell-matrix compositions of the present invention do not require long-term incubation or cultivation in vitro prior to use in in vivo applications. The stem cells can be from numerous sources and may be homogeneous, heterogeneous, autologous, and/or allogeneic in the matrix material. The stem cell-matrix compositions as described provide point of service utility for the practitioner, wherein the stem cells and matrix can be combined not long before use, thereby alleviating costly and lengthy manufacturing procedures. In addition, the stem cells offer unique structural properties to the matrix composition which improves outcome and healing after use. Use of stem cells obtained from muscle affords contractility to the matrix composition.

Claims

1. A rapid method of preparing a stem cell-biomatrix for use in tissue and organ treatment or repair comprising:

a) admixing a stem cell preparation with a physiologically acceptable matrix material to form a stem cell matrix; and

b) incubating the stem-cell matrix of step a in vitro for less than about 12 hours prior to use in tissue or organ treatment or repair in a recipient.

2. The method according to claim 1, wherein the stem cells are autologous to the recipient.

3. The method according to claim 1, wherein the stem cells are allogeneic to the recipient.

4. The method according to claim 1, wherein the physiologically acceptable matrix material is absorbable or non-absorbable.

5. The method according to claim 1 or claim 4, wherein the matrix material is selected from the group consisting of small intestine submucosa (SIS), crosslinked alginate, bioadhesives, hydrocolloid, collagen gel, collagen sponge, polyglycolic acid (PGA) mesh, polyglactin (PGL) mesh, fleeces and dead de-epidermized skin equivalents in one or more layers.

6. The method according to claim 1, wherein homogeneous or heterogeneous populations of stem cells are admixed with the matrix material.

7. The method according to claim 1 or claim 6, wherein the stem cells are obtained from tissues selected from the group consisting of bone marrow, muscle, adipose, liver, heart, lung and nervous system.

8. The method according to claim 7, wherein the tissues are selected from the group consisting of adult, embryonic or fetal tissues.

9. The method according to claim 1 or claim 6, wherein the stem cells are obtained from muscle.

10. The method according to claim 9, wherein the stem cell matrix is contractible.

11. The method according to claim 1, wherein the stem cells are introduced into the physiologically acceptable matrix material so as to deposit from about 2.5×

103 to about 1×

10⁶ stem cells in the matrix material.

12. The method according to claim 11, wherein the stem cells are introduced into the physiologically acceptable matrix material so as to deposit from about 5×

10³ to about 1×

10⁶ stem cells in the matrix material.

13. The method according to claim 1, wherein the stem cells are introduced into the physiologically acceptable matrix material so as to deposit about 1×

10⁵ stem cells per 1 cm² of matrix.

14. The method according to claim 1, wherein the stem cells are incubated with the matrix material in vitro for less than about 3 hours prior to being used for tissue or organ repair.

15. The method according to claim 1, wherein the stem cells are incubated with the matrix material in vitro for less than about 1 hour prior to being used for tissue or organ repair.

16. The method according to claim 1, wherein the stem cells are incubated with the matrix material in vitro for less than about 30 minutes prior to being used for tissue or organ repair.

17. The method according to claim 1, wherein the stem cells are incubated with the matrix material in vitro from about 5 seconds to about 30 minutes prior to being used for tissue or organ repair.

18. The method according to claim 1, wherein the tissue or organ repair are selected from the group consisting of wound healing, surgical incision repair, tissue augmentation, organ augmentation, smooth muscle repair, non-smooth muscle repair and blood vessel repair.

19. The method according to claim 1, wherein the stem cells used for tissue or organ repair are attached to the matrix material using biological adhesives.

20. The method according to claim 1, wherein the stem cells alter biomechanical properties of the matrix material.

21. A composition comprising stem cells and a physiologically acceptable matrix material forming a stem cell matrix prepared according to claim 1.

22. The composition according to claim 21, wherein the stem cell matrix is contractible.

24. The method according to claim 23, wherein the stem cells are autologous to the recipient.

25. The method according to claim 23, wherein the stem cells are allogeneic to the recipient.

26. The method according to claim 23, wherein the first and second physiologically acceptable matrix materials are absorbable or non-absorbable.

27. The method according to claim 23, wherein the first physiologically acceptable matrix material is selected from the group consisting of crosslinked alginate, hydrocolloid, collagen gel and bioadhesives;

and wherein the second physiologically acceptable matrix material is selected from the group consisting of small intestine submucosa (SIS), collagen sponge, polyglycolic acid (PGA) mesh, polyglactin (PGL) mesh, fleeces and dead de-epidermized skin equivalents in one or more layers.

28. The method according to claim 23, wherein homogeneous or heterogeneous populations of stem cells are admixed with the first or second matrix material.

29. The method according to claim 23, wherein the stem cells are obtained from tissues selected from the group consisting of bone marrow, muscle, adipose, liver, heart, lung and nervous system.

30. The method according to claim 29, wherein the tissues are selected from the group consisting of adult, embryonic and fetal tissues.

31. The method according to claim 23, wherein the stem cells are introduced into the physiologically acceptable matrix material so as to deposit from about 2.5×

10³ to about 1×

10⁶ stem cells in the matrix material.

32. The method according to claim 31, wherein the stem cells are introduced into the physiologically acceptable matrix material so as to deposit from about 5×

10³ to about 1×

10⁶ stem cells in the matrix material.

33. The method according to claim 23, wherein the stem cells are introduced into the physiologically acceptable matrix material so as to deposit about 1×

10⁵ stem cells per 1 cm² of matrix.

34. The method according to claim 23, wherein the second stem cell-matrix material functions at the tissue or organ sites in medical procedures selected from the group consisting of wound healing, surgical incision repair, tissue augmentation, organ augmentation, smooth muscle repair, non-smooth muscle repair and blood vessel repair.

35. The method according to claim 23, wherein the stem cells alter biomechanical properties of the second matrix material.

36. The method according to claim 23, wherein the stem cell matrix is contractible.

37. The method according to claim 1 or claim 23, wherein the stem cell-matrix is applied to a tissue or organ site by a mode selected from the group consisting of spraying, painting, coating and spreading.

39. The preparation according to claim 38, wherein the substrate material is small intestine submucosa (SIS).

40. The preparation according to claim 38, wherein stem cells are autologous to a recipient of the preparation.

41. The preparation according to claim 38, wherein the stem cells are allogeneic to a recipient of the preparation.

42. The preparation according to claim 38, wherein the stem cells are obtained from muscle.

43. The preparation according to claim 38, wherein the stem cells are obtained from skeletal muscle.

44. The preparation according to claim 42 or claim 43, comprising a three-dimensional muscle replacement having muscle contractility.

45. The preparation according to claim 44, further wherein the substrate material is small intestine submucosa (SIS).

23. A rapid method of preparing a stem cell-biomatrix for use in tissue and organ treatment or repair comprising:

a) admixing a stem cell preparation with a first physiologically acceptable matrix material to form a first stem cell-matrix combination;

b) introducing the first stem cell-matrix combination of step a) onto a second physiologically acceptable matrix material to form a second stem cell-matrix material, wherein the first stem cell-matrix combination and the second physiologically acceptable matrix material are incubated in vitro for between about 5 seconds and 1 hour; and

c) applying the second stem cell-matrix material of step b on or in a tissue or organ site in a recipient.

38. A preparation of stem cells and a physiologically acceptable substrate material forming an implantable and innervatable three-dimensional scaffolding for tissue and organ repair.